CareDx (CDNA)
NASDAQ:CDNA
Want to see CDNA full AI Analyst Report?
CDNA Stock Chart & Stats
$21.42
$0.67(2.95%)
At close: 4:00 PM EST
$21.42
$0.67(2.95%)
Day’s Range― - ―
52-Week Range$10.96 - $29.07
Previous CloseN/A
Volume177.07K
Average Volume (3M)1.12M
Market Cap
$1.49B
Enterprise Value$1.16B
Total Cash (Recent Filing)$187.18M
Total Debt (Recent Filing)$24.50M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Jul 30, 2026EPS Estimate
0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding51,659,480
10 Day Avg. Volume957,989
30 Day Avg. Volume1,123,784
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)3.31
Price to Sales (P/S)2.64
P/FCF Ratio27.80
Enterprise Value/Market Cap0.78
Enterprise Value/Revenue2.81
Enterprise Value/Gross Profit4.10
Enterprise Value/Ebitda108.40
Forecast
1Y Price Target
$28.00Price Target Upside30.72% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)0.93
Revenue Forecast (FY)$455.96M
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationCareDx converted to materially positive and growing cash flow (TTM OCF ~$72.9M; FCF ~$65.2M; FCF growth +78.8%). Durable cash generation supports reinvestment, buybacks, M&A funding and buffers reimbursement volatility, improving financial flexibility over the next 2-6 months.
Conservative Balance Sheet / LiquidityVery low leverage (debt-to-equity ~0.06) and meaningful liquidity provide a strong financial cushion. This reduces refinancing risk, enables strategic actions (divestiture, acquisition, buyback) and preserves optionality to invest in scaling operations or absorb short-term reimbursement shifts.
Strategic Portfolio Simplification And Targeted M&AThe planned Lab Products divestiture sharpens focus on higher-growth testing services and digital solutions while generating ~$160M net proceeds. The Navaris acquisition expands addressable markets (oncology MRD) with Medicare coverage and ADLT reimbursement, strategically diversifying revenue drivers longer term.
Bears Say
Inconsistent GAAP ProfitabilityDespite revenue re-acceleration and robust gross margins, GAAP profitability remains inconsistent (TTM net margin ~-5.6%, operating loss). Persistent profit volatility undermines durable earnings conversion and could constrain sustainable margin expansion or shareholder returns absent continued operational improvement.
Reimbursement / LCD Regulatory RiskReimbursement determinations like a MolDX LCD can structurally reduce per-test reimbursement or coverage scope. A modeled $7.5M 2026 impact illustrates sensitivity: regulatory shifts can durably lower revenue per test and margin profile, making long-term cash flow less predictable.
Navaris Integration And Scale Execution RiskAcquiring Navaris expands addressable markets but requires successful automation to lower cost-per-test, further clinical validation for some indications, and careful reimbursement management. Execution, integration costs and potential reimbursement resets could persistently pressure incremental margins and cash conversion.
CareDx News
CDNA FAQ
What was CareDx’s price range in the past 12 months?
CareDx lowest stock price was $10.96 and its highest was $29.07 in the past 12 months.
What is CareDx’s market cap?
CareDx’s market cap is $1.49B.
When is CareDx’s upcoming earnings report date?
CareDx’s upcoming earnings report date is Jul 30, 2026 which is in 33 days.
How were CareDx’s earnings last quarter?
CareDx released its earnings results on Apr 28, 2026. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.134 by $0.206.
Is CareDx overvalued?
According to Wall Street analysts CareDx’s price is currently Undervalued.
Does CareDx pay dividends?
CareDx does not currently pay dividends.
What is CareDx’s EPS estimate?
CareDx’s EPS estimate is 0.23.
How many shares outstanding does CareDx have?
CareDx has 51,659,480 shares outstanding.
What happened to CareDx’s price movement after its last earnings report?
CareDx reported an EPS of $0.34 in its last earnings report, beating expectations of $0.134. Following the earnings report the stock price went down -5.066%.
Which hedge fund is a major shareholder of CareDx?
Currently, no hedge funds are holding shares in CDNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CareDx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$28.00 (30.72% Upside)
$28.00 (30.72% Upside)
Hedge Fund Trend
Increased
By 91.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $214.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.6%
Last 30 Days ▲ 17.0%
Last 30 Days ▲ 17.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.91%
12-Months-Change
Fundamentals
Return on Equity
-2.61%
Trailing 12-Months
Asset Growth
-16.05%
Trailing 12-Months
Company Description
CareDx
CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
CDNA Company Deck
CDNA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong top-line growth, substantial margin and EBITDA improvement, raised full‑year guidance, a strategic simplification via a Lab Products divestiture (expected ~$160M net proceeds), and a targeted acquisition (Navaris) that expands addressable markets with strong clinical evidence and favorable reimbursement. Challenges include modest profitability and declining trends in the Lab Products segment prior to divestiture, revenue recognition timing noise, reimbursement/LCD risk (~$7.5M modeled headwind), elevated operating expenses and uncertainty in transplant procedure volumes, and integration/scale risks for Navaris and the product carve-out. On balance, the positive growth, improved profitability, cash position, and strategic actions outweigh the execution and timing risks discussed on the call.View all CDNA earnings summariesCDNA Stock 12 Month Forecast
Average Price Target
$28.00
▲(30.72% Upside)
Technical Analysis
Ownership Overview
4.97% Insiders
19.86% Mutual Funds
48.23% Other Institutional Investors
6.15% Public Companies and
Individual Investors